An overview of crucial genes involved in stemness of glioblastoma multiforme

被引:0
作者
Reza Ahmadi-Beni
Alireza Khoshnevisan
机构
[1] Tehran University of Medical Sciences,Department of Medical Genetics, School of Medicine
[2] Tehran University of Medical Sciences,Department of Neurosurgery, Shariati Hospital
来源
Neurochemical Journal | 2017年 / 11卷
关键词
glioblastoma multiforme; cancer stem cells; stemness genes; GSC regulators; molecular targeted therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Glioblastoma multiforme (GBM) is the most common and first leading cause of death in primary human brain cancers. Following current interventions, despite continuous advancements in medicine, the median survival time of patients is unfavorable regardless of radiotherapy, chemotherapy, or surgery. This poor outcome is referred to “cancer stem cell” (CSC) concept. According to it a minority of cells within the GBM mass originates from neural stem cells (NSCs) or alternatively hijack similar checkpoints in them that evolution has selected in order to prevent inappropriate neurogenic-to-gliogenic switch which is responsible for the growth of tumor and its resistance to existing therapies. New developments in non-surgical treatment of GBM are based on this knowledge, however, similarities in molecular pathways between GBM and glioma stem cells (GSCs) motive the race to identify and target GSC regulators with less and more harmful effect in normal adult NSC and GBM respectively. In it the implications of downstream stemness genes with modulatory roles for stemness state pathways are assumed importance. This review, embodies NSC-intrinsic genes by recent elucidated roles of importance for GBM to affix to the stemness. Therefor it could facilitate a holistic approach of molecular targeted therapy to compromise the formidable resistant GBM to eradication.
引用
收藏
页码:259 / 265
页数:6
相关论文
共 759 条
[1]  
Safari M.(2015)undefined J. Stem Cells 10 271-285
[2]  
Khoshnevisan A.(2012)undefined Med. J. Islam. Repub. Iran 26 31-40
[3]  
Khoshnevisan A.(2003)undefined Nat. Rev. Cancer. 3 895-902
[4]  
Pardal R.(2001)undefined Nature 414 105-111
[5]  
Clarke M.F.(2009)undefined Mol. Ther. 17 219-230
[6]  
Morrison S.J.(2015)undefined Front. Oncol. 5 159-910
[7]  
Reya T.(2010)undefined Neuropharmacology 58 903-6550
[8]  
Morrison S.J.(2009)undefined Clin. Cancer Res. 15 6541-2243
[9]  
Clarke M.F.(2013)undefined Exp. Cell Res. 319 2230-26215
[10]  
Weissman I.L.(2015)undefined Oncotarget. 6 26192-6834